Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Randomized controlled trials (RCTs) continue to be the basis for essential evidence regarding the efficacy of interventions such as cancer therapies. Limitations associated with RCT designs, including selective study populations, strict treatment regimens, and being time-limited, mean they do not provide complete information about an intervention’s safety or the applicability of the trial’s results to a wider range of patients seen in real-world clinical practice. For example, recent data from Alberta showed that almost 40% of patients in the province’s cancer registry would be trial-ineligible per common exclusion criteria. Real-world evidence (RWE) offers an opportunity to complement the RCT evidence base with this kind of information about safety and about use in wider patient populations. It is also increasingly recognized for being able to provide information about an intervention’s effectiveness and is considered by regulators as an important component of the evidence base in drug approvals. Here, we examine the limitations of RCTs in oncology research, review the different types of RWE available in this area, and discuss the strengths and limitations of RWE for complementing RCT oncology data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These observational studies are at moderate to high risk of bias and have several limitations that hinder causal inference, including lack of randomization and reliance on medical claims and medical record documentation for the evaluation of exposure (e.g.,. GLP-1 RA use) and outcomes (e.g., thyroid cancer and subtypes).50”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Observational studies using data generated as part of clinical practice can provide real-world evidence of effectiveness and safety. Yet, they are prone to confounding and biases that hinder causal inference, in this case, supporting a causal association between GLP-1 RA use and development or diagnosis of thyroid cancer.49,50”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., & Johnston, J. (2015) · Trials · doi:10.1186/s13063-015-1023-4 · Cited by 878
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739
Desai, R. J., & Franklin, J. M. (2019) · BMJ · doi:10.1136/bmj.l5657 · Cited by 657
Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocaña, A. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr242 · Cited by 622
Cited by
ESMO guidance for reporting oncology real-world evidence (GROW)
Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.001 · Cited by 247
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
Castelo-Branco, L., Pellat, A., Martins-Branco, D. A., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U. G., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2023.10.001 · Cited by 41
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“49,50 T h e l ea v e on e - ou t a n a l y s i s s ho w e d t h a t t h e e x c l u s i on o f non e o f t h e i n c l ud e d s t ud i e s m od i fi e d t h e e x t e n t o f t h e e ff ec t , bu t l ea v e ou t o f fi v e s t ud i e s w e r e i d e n ti fi e d w ho s e e x c l u s i on w ou l d l ea…”
stefanolo, J. P., Segura, V., Grizzuti, M., Heredia, A., Comino, I., Costa, A. F., Puebla, R. A., Temprano, M. P., Niveloni, S. I., de Diego, G. A., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i11.1545 · Cited by 32
“Consequently, the enforced stay-at-home measures during this time may have contributed to improved adherence to the GFD, as has been suggested by a recent study[31].”
Gandaglia, G., Pellegrino, F., Golozar, A., Meulder, B. D., Abbott, T., Achtman, A. H., Omar, M. I., Alshammari, T. M., Areia, C. M., Asiimwe, A., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.06.012 · Cited by 20
“Therefore, these might be less generalizable at a population level, where 40% of cancer patients would be eligible in RCTs [9].”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk
Ho, C., Ayers, A. T., Kohn, M. A., Umpierrez, G. E., & Klonoff, D. C. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf088 · Cited by 19
“Furthermore, side effects might be identified in patient subgroups often excluded from RCTs, such as elderly patients or those with comorbidities [28].”
O’Sullivan, J. M., McKay, R. R., Rahbar, K., Fizazi, K. S., George, D. J., TOMBAL, B. F., Schmall, A., Sandström, P., Verholen, F., & Shore, N. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1070392 · Cited by 15
Ellis, P. M., Long, L., Coschi, C. H., & Sathiyapalan, A. (2025) · Current Oncology · doi:10.3390/curroncol32110629 · Cited by 13
“…[11,12,16,19,22,25,27] 7 Increased external validity [12,22,23,25,27] 5 Increased identification of important cohorts for stratification [10,20,21,28] 4 Translation of RCT outcomes into clinical practice [10,19,27,28] 4 Hypothesis-generating [10,19,28] 3 Creation of multi-purpose data…”
Kim, T., Lee, M. S., Birch, S., Alræk, T., Norheim, A. J., & Kang, J. W. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20577 · Cited by 15
Enrico, D. H., Gomez, J., Aguirre, D., Tissera, N. S., Tsou, F., Pupareli, C. S., Tanco, D. P., Waisberg, F., Rodríguez, A., Rizzo, M., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.09.005 · Cited by 14
Moldovianu, A.-M., Stoia, R. A., Vasilică, M., Ursuleac, I., BADELITA, S. N., Tomescu, A. A., Preda, O. D., Bardaş, A., Cirstea, M., & Coriu, D. (2023) · Medicina · doi:10.3390/medicina59020324 · Cited by 11
Pattipaka, T., Sarp, S., Nakhaei, P., & Güneş, S. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02207-4 · Cited by 9
Hosseini-Mellner, S., Wickberg, Å., Karakatsanis, A., & Valachis, A. (2024) · The Breast · doi:10.1016/j.breast.2024.103741 · Cited by 9
“The inherent risk of bias when different treatment strategies are compared in real-world setting without random treatment allocation poses challenges in the interpretation of study results [16].”
Backgroundda Costa, F. A., Borges, F. C., Ramos, A., Mayer, A., Brito, C., Ramos, C., Bernardo, C., Cossito, M., Furtado, C. D., Ferreira, A. R., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01678-5 · Cited by 8
Odisio, B. C., Wah, T. M., Fotiadis, N., Anton, K., Yoon, C. J., Stanziola, J., Mamun, A., Meyers, E. E., & León, H. D. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.01.035 · Cited by 7
Langheinrich, M. C., Gerken, M., Robers, G., Hansinger, J., Franke, B., Lacruz, M. E., Müeller-Nordhorn, J., Schneider, C., Reinwald, F., Stang, A., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115583 · Cited by 7
Kattenhøj, K. D., Møberg, C. L., Guldbrandt, L. M., Friis, R. B., Mapendano, C. K., Petersen, S. K., Ruhlmann, C. H. B., Svane, I. M., Donia, M., Ellebæk, E., et al. (2024) · Cancers · doi:10.3390/cancers16142559 · Cited by 6
“These factors all help to enhance the external validity and generalizability of the studies, making RWD such as the data from the DAMMED database [5] an important part of evidence-based medicine [10].”
BackgroundDrug-induced agranulocytosis: a disproportionality analysis and umbrella review
Lu, Y., Wu, B. Y., Li, K., Liu, Z., Chen, Y., & Xu, T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1641747 · Cited by 6
“To address this situation, real-world evidence (RWE) served as a valuable supplement, with a wide range of data sources that enabled it to re fl ect potential ADE in different populations and various clinical settings (Azoulay, 2022).”
Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park‐Simon, T., Untch, M., & Lux, M. P. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2344-5269 · Cited by 6
“Patients with endocrine”
Fairman, C. M., Harrington, S., Schumpp, A., Brooks, A. M., Jones, M. J., Kim, J. S., & Kennedy, M. A. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11797-0 · Cited by 5
“Traditional approaches to clinical research trials are not sufficient to make exercise standard of care, in part because clinical trials have a limited capacity to serve people in the target population [27, 28].”
BackgroundTheophanous, S., Lønne, P.-I., Choudhury, A., Berbée, M., Deijen, C. L., Dekker, A. L. A. J., Field, M., Gambacorta, M. A., Gilbert, A., Guren, M. G., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70297-3 · Cited by 6
Real-World Evidence Studies in Oncology Therapeutics: Hope or Hype?
Thakur, S. (2023) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-023-01784-y · Cited by 6
“For example, the treatment option in BRAF mutated metastatic melanoma is rapidly evolving given seven new therapies were approved between 2014 and 2018 [34].”
Kim, M. J., Kim, H. J., Kim, J., Shin, J., & Park, Y. H. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.12.019 · Cited by 5
Porter, D., Klink, A. J., Balanean, A., Schuler, T. A., Kalesan, B., Swain, R. S., McAllister, L., Liassou, D., Lucht, S. A., Gajra, A., et al. (2025) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2025.100200 · Cited by 4
van der Galiën, H. T., Kooistra, H., Kibbelaar, R. E., Veeger, N. J. G. M., Nijland, M., Huls, G. A., van Meerten, T., & van Rijn, R. S. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70003 · Cited by 4
“In routine clinical practice, most lymphoma patients are treated outside of RCTs and in non-academic settings, where variations in disease characteristics, treatment histories and comorbidities may negatively impact outcomes [12–14].”
Doyle, C., Lohmann, A. E., Iqbal, N., Henning, J., Kulkarni, S., Califaretti, N., Hilton, J. F., Ferrario, C., Bouganim, N., Mates, M., et al. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07580-8 · Cited by 4
“An in-depth understanding of the various therapies can be better comprehended when information from RCT is supplemented with real-world evidence [19–21].”
Collet, R. J., Ben, Â. J., Varga, A. N., van Leth, F., Alili, M. E., Eßer, J., Bosmans, J. E., & van Dongen, J. M. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70013 · Cited by 4
Robinson, S. I., Klein, A., Stanhope, S. A., Evans, K., & Agulnik, M. (2025) · Future Oncology · doi:10.1080/14796694.2025.2502319 · Cited by 3
“Clinical trials are considered the gold standard for data on drug efficacy and safety; however, the patient populations in these studies do not always reflect the real-world population [30].”
Christopoulos, P., Assmann, C., Zhang, L., Dunton, K., Ali, A., Berktaş, M., Delmastro, L., Strübing, A., Xiong, Y., Lay-Flurrie, S. L., et al. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.09.019 · Cited by 3
Трофимов, А. Н., Shcherbakova, K., Schwarz, A. P., Akbay, B., Karapina, O., Myrkhiyeva, Z., Shirokov, E., Kizatov, B., Zhukanov, K., Baktursyn, A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156606 · Cited by 3
van den Berg, K., van Erning, F. N., Burger, J. W. A., van Hellemond, I. E. G., Roodhart, J. M. L., Koopman, M., Rutten, H. J. T., & Creemers, G. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.02.006 · Cited by 3
Butterworth, V., Young, T., Drake, H., Palmer, I., Avgoulea, T., Ivy, E., Andriolo, J., Creppy, C., Routledge, C., Adjogatse, D., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100162 · Cited by 3
Perrone, V., Leogrande, M., Cappuccilli, M. L., Saragoni, S., Luciani, A. C., & Esposti, L. D. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s496606 · Cited by 3
Baek, S. K., Jeong, J.-H., Jung, K. H., Ahn, H. K., Kim, M. H., Sohn, J., Park, I. H., Ahn, J. S., Lee, D., Im, S., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225029 · Cited by 2
Müller, J. A., Bedir, A., Katalinic, A., Oesterling, F., Graw, A., Kluttig, A., Corradini, S., Vordermark, D., & Medenwald, D. (2025) · Strahlentherapie und Onkologie · doi:10.1007/s00066-025-02486-w · Cited by 2
Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?
Bermejo, B., Dienstmann, R., Bellet, M., de la Cruz, S., Galve-Calvo, E., Obadía, V., Santaballa, A., Ramos‐Medina, R., Cuenca, M., & Moreno, F. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0186 · Cited by 2
“Inverse probability of treatment weighting is a traditional propensity score weighting approach (Figure 2) [5] .”
InfluentialLazaridou, E., Kourlaba, G., Ravanidis, S., Gounelas, G., Stefanou, G., Tsolakidis, A., Mathioudakis, K., & Apalla, Z. (2024) · Clinical and Experimental Dermatology · doi:10.1093/ced/llae240 · Cited by 2
Mahtani, R. L., Harpalani, N., Yan, F., Phiel, K. L., & Kovalenko, I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1419246 · Cited by 2
Sammons, S. L., Yardley, D. A., Sharma, P., Gadi, V. K., Pegram, M. D., Pathak, P., Hu, H., Sopher, G. M., & Fasching, P. A. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00394-8 · Cited by 2
“The predefined inclusion criteria, highly specific treatment protocols, and constrained duration and follow-up periods, are characteristics of RCTs which limit the applicability of RCT findings to broader clinical settings [1, 19].”
InfluentialAlekhina, N., Mooney, K., Sward, K. A., Wong, B. G., & Akerley, W. (2026) · Research Square · doi:10.21203/rs.3.rs-10233239/v1 · Cited by 2
Malignant melanoma in Portuguese adult population: a scoping review of the real-world evidence
Gouveia, E. J., Sousa, R., Aguiar, S. I., Gírio, A., Costa, I. M., Dionísio, M. R., & Moital, I. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03579-1 · Cited by 1
“…to complement the RCT evidence base information about effectiveness, safety and use in wider patient populations, as well as to assess the natural history of the disease, its prevalence and incidence rates, unmet medical care needs, current treatment approaches, and standard of care [10, 11].”
Szamreta, E. A., Modi, M., Periyasamy, R., Yamsani, B., Machiraju, P., Menghani, N., & Monberg, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321654 · Cited by 1
“Moreover, RWE provides a comprehensive view of treatment performance in routine clinical practice, allowing for tailored treatments to individual needs, ultimately improving outcomes and guiding policy decisions [17].”
Zhang, B., Ning, F., Liu, X., Li, N., Wang, P., Yao, W., Han, B., Wang, Q., & Zhong, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1625714 · Cited by 1
UK real-world data of radium-223 dichloride in metastatic prostate cancer
Randhawa, M., Buchanan, G., STRATTON, I. M., Race, G., Challapalli, A., Bottomley, D., Logue, J. P., Sundar, S., Robinson, A. J., McLaren, D. B., et al. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002050 · Cited by 1
“Such comparisons may be confounded due to differences in clinical and blood parameters [12] and lead time bias.”
Target trial emulation in oncology: current use and future directions
Huang, H., Wang, L., Xu, S., Jia, S., Kong, D., Zhang, X., Wang, S., He, H., Chen, H.-R., Xia, L.-Z., et al. (2026) · Military Medical Research · doi:10.1186/s40779-026-00685-9 · Cited by 1
“Conducting RCTs for every relevant clinical question in oncology is therefore neither feasible nor ethical, especially for rare cancers, elderly or frail populations, or for rapid post-approval evidence generation [8].”
Hale, J., Gilbert, T. M., Stott, M. C., Whelan, P., Jackson, R., Wong, H., McKay, M., Ghaneh, P., Halloran, C. M., Faluyi, O. O., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03341-0 · Cited by 1
“…always re fl ect real world outcomes, and frequently include younger patients with more favourable prognostic factors (e.g., low CA19-9) and better fi tness, as well as representing a cohort of patients, who by virtue of participating in research, may be inherently more supported and motivated [10].”
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study
Swain, R. S., Klink, A. J., Asgarisabet, P., Savill, K. M. Z., Kalesan, B., Balanean, A., Hays, H. D., Kaufman, J., McAllister, L., Omary, C. S., et al. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0134 · Cited by 1
Zhang, Y. (2026) · American Journal of Translational Research · doi:10.62347/jqhn3788 · Cited by 1
Bukovac, J., Husain, M., Sapper, T. N., O’Dell, A., Bittoni, M. A., Gastier, H., Chebbi, A., Hockenhull, V., Dohar, Z., Moon, J., et al. (2026) · Nutrition and Cancer · doi:10.1080/01635581.2026.2658807 · Cited by 1
Olsson, M., Janeva, S., Martikainen, J., Tzikas, A.-K., Karlsson, P., & Parris, T. Z. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07983-9 · Cited by 1
Debieuvre, D., Macouillard, P., Quantin, X., BERKTAŞ, M., Girard, N., Audigier-Valette, C., Filleron, T., Musilli, S., Bosquet, L., & Pérol, M. (2026) · Cancer Medicine · doi:10.1002/cam4.71975 · Cited by 1
Porges, T., Levi, T., Dann, E. J., Aumann, S., Gurion, R., Buchrits, S., Perry, C., Vitkon, R., Levi, I., Ilan, E., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70682 · Cited by 1
“12 The current study has aimed to evaluate the outcomes of patients with advanced-stage cHL treated with the BrECADD regimen in real-world settings and to determine whether clinical trial results are reproduced in routine practice.”
Su, L., Chen, L., Mamtani, R., Betigeri, S., Hubbard, R. W., & Burcu, M. (2026) · The Oncologist · doi:10.1093/oncolo/oyag296 · Cited by 1
Altini, M., Amunni, G., Baldessin, L., Brignoli, O., Capuano, A., Conte, P., Danesi, R., Maio, M. D., Dondi, L., Fioretto, L., et al. (2025) · Annals of Research in Oncology · doi:10.48286/aro.2025.104 · Cited by 1
Gebrye, T., Mbada, C. E., Hakimi, Z., & Fatoye, F. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70052 · Cited by 1
Sukkarieh, H. H., Fayez, N. A., Al‐Omar, H. A., Azmi, N. O., Syed, B. U. A., Albar, R. A., & Bali, N. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1712147 · Cited by 1
“This limitation highlights the need for RWE, which is generated during routine clinical practice and on other relevant platforms (Azoulay, 2022; Peng et al., 2022).”
Soliman, R. (2023) · Cochrane Evidence Synthesis and Methods · doi:10.1002/cesm.12010
“Generally, real ‐ world data studies can be limited by potential biases during study design or result interpretation; heterogeneity in quality of real ‐ world data; and limited generalizability of results [20, 25].”
Lejas, J., Leterrier, L., Mottin, D., Timsit, J., Troussard, X., Lévy, V., & Chevret, S. (2023) · Research Square · doi:10.21203/rs.3.rs-4231024/v1
Minhinnick, A., Dunn, A., Arabnejad, V., Paddison, J. S., Jackson, C., Pointer, S. M., Gurney, J., & Cameron, L. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00483
Lai, L. Y. H., Sakalis, V. I., Chatzichristos, C., de la Parra, I., Steinbeißer, C., Golozar, A., Meulder, B. D., Hijazy, A., Snijder, R. J., Feng, Q., et al. (2024) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2024.83
Regueiro, M. D., Bewtra, M., Dubinsky, M. C., Branquinho, D. F., Feng, C., McDonnell, A., & Gianfrancesco, M. A. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf067
“16 Additionally, many rare safety events are not observed in phase 3 clinical trials due to relatively small population sizes and limited duration of follow-up.”
Tran, B., Yeh, N., Gayle, A., Holmes, E., Hu, J., Damineni, S., Kebede, N., & Shore, N. D. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100149
“Accounting for variation in drug exposure remains a challenge for RWD studies, 14 and capturing total ADT exposure time can be complicated by switching ADT, intermittent ADT use, or resuming ADT in a later line of therapy.”
Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park‐Simon, T., Untch, M., & Lux, M. P. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2579-9530
“Ein Therapieeffekt im Hinblick auf die Wirksamkeit, Sicherheit und Verträglichkeit lässt sich also in einer im Vergleich zu RCTs breiteren Population zeigen, welche die Therapierealität besser abbildet [64].”
Samani, A., Giannone, G., Mercuri, L., Jiang, R., Nadkarni, Y., Chadha, A., Xing, E., Ghaem‐Maghami, S., Krell, J. M., Lyons, D., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100150
Spagnuolo, M. C., Shogry, F. F., Park, S., Bakewell, N., Hayes, K. N., Burden, A. M., Hundal, A. K., & Cadarette, S. M. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07745-1
“Although the ITT approach is the “gold standard” in RCTs to preserve randomization, flexible exposure definitions are needed in real-world studies to account for the changes in treatment approaches to achieve optimal treatment responses [28, 31].”
Alves da Costa, F., Borges, F. C., Ramos, A., Mayer, A., Brito, C., Ramos, C., Bernardo, C., Cossito, M., Furtado, C. D., Ferreira, A. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23606944
Lialina, E. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Spilles, S. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Real-world evidence to accelerate knowledge in gynecologic oncology
Chiva, L. M., Mínguez, J. Á., Chacón, E., & González, A. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.104464
Lee, K., Oh, H., Jeong, H., Kim, B. J., Han, M., Kim, J.-T., Choi, K., Shin, D., Cha, J., Kim, D., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045364
“11,12 Well-designed and implemented prospective registries can help to bridge this gap by capturing real-world treatment patterns across diverse populations.”
Turhan, A., & Özyurt, N. (2026) · Journal of Medicine and Palliative Care · doi:10.47582/jompac.1855426
Real-World Outcomes of an Exercise Program Following Hematopoietic Stem Cell Transplantation
Marvin, S. C., Ross, L. S., Kay, S., Lacey, J., Edwards, K. M., & Yee, J. (2026) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000348
Big data–driven observational evidence in Korea: challenges in interpreting non-randomized studies
Choi, J. H. (2026) · Journal of Evidence-Based Practice · doi:10.63528/jebp.2026.00003
“Ethical constraints, feasibility limitations, long follow-up requirements, rapidly evolving standards of care, and the growing need to evaluate real-world effectiveness have increasingly highlighted the limitations of an RCT-only paradigm [3,4].”
Anticoagulation during anti-angiogenic cancer therapy: balancing risks of thrombosis and bleeding
Vladić, N., & Moik, F. (2026) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2026.452
Gualerzi, A. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Kıkılı, C. İ., Araz, M., Ürün, Y., Başaran, M., Şener, N., Yazar, A., Ay, S., Kılıçkap, S., Erman, M., Şimşek, E. T., et al. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102594
Are respiratory physicians adherent to guidelines when evaluating pulmonary nodules?
Tu, L., Wong, R. W. S., Baker, A., O’Donoghue, F. J., McDonald, C., & Leong, T. L. (2026) · Internal Medicine Journal · doi:10.1111/imj.70491
Strategies to accelerate evidence generation and application in colorectal cancer care
Chia, B. J. (2026) · cIRcle (University of British Columbia) · doi:10.14288/1.0452709
Shi, D., Li, X., Chen, Y., Chen, Y. M., Song, Q., & Su, J. (2026) · medRxiv · doi:10.64898/2026.06.30.26356941
Zhang, J., Xu, M., Mao, J., Ma, J., & Wang, H. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-26
Pluard, T., Grinda, T., Dienstmann, R., Thill, M., Korytowsky, B., Chen, C. X., Portuhay, S., Salvo‐Halloran, E. M., Samjoo, I. A., & Harbeck, N. (2026) · Cancers · doi:10.3390/cancers18142362
“For example, recent data suggest that up to 40% of patients in cancer registries may be ineligible for participation in RCTs [8].”
Teppala, S., Koo, J., Tan, E. C. K., Clarke, S. J., & Lu, C. Y. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02202-3
Владимирович, С. А., & Кононенко, И. Б. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2026.2.203708
Li, Y., Zhai, L., Wang, L., Deng, S., Zhao, B., Niu, H., Zhang, L., & Gao, X. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002887
Qiu, H., Zhuang, L., Dai, J., Shi, Q., Ding, L., & Qiu, W. (2026) · Translational Pediatrics · doi:10.21037/tp-2026-0650
Metadata
- Authors
- Azoulay, L.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Azoulay, Laurent
- ORCID
- Azoulay, Laurent
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-06-28
- Volume
- 27
- Issue
- 9
- Pages
- e731-e738
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC9438907
- OpenAlex
- W4283693701
- Semantic Scholar
- be428d13a690826d0c488243ced0486f25cb7e18
- Cited by
- 79
- References
- 52
- Citations by year
- 2026: 24 · 2025: 28 · 2024: 15 · 2023: 11 · 2022: 1
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer Canada
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- real-world evidence, oncology, randomized controlled trials, inclusion and exclusion criteria, cancer registry, drug approval, drug safety, effectiveness
- MeSH terms
- Canada, Humans, Medical Oncology, Neoplasms, Registries, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.